Characterisation of the Faecal Microbiota in Dogs with Mast Cell Tumours Compared with Healthy Dogs
- PMID: 40804998
- PMCID: PMC12345436
- DOI: 10.3390/ani15152208
Characterisation of the Faecal Microbiota in Dogs with Mast Cell Tumours Compared with Healthy Dogs
Abstract
Mast cell tumours (MCT) are the most common cutaneous neoplasms in dogs, with variable behaviours and patient survival time. Both indolent and aggressive forms have been described, but much remains to be explored regarding prognosis and therapy. Evidence has highlighted the influence of microbiota on multiple health and disease processes, including certain types of cancer in humans. However, knowledge remains scarce regarding microbiota biology and its interactions in both humans and canine cancer patients. This study aimed to characterise the faecal microbiota of dogs with MCT and compare it with that of healthy individuals. Twenty-eight dogs diagnosed with MCT and twenty-eight healthy dogs were enrolled in the study. Faecal samples were collected and analysed by Illumina sequencing of 16S rRNA genes. Alpha diversity was significantly lower in dogs with cancer, and the species diversity InvSimpson Indexwas reduced (p = 0.019). Principal coordinate analysis showed significant differences in the bacterial profile of the two groups: there was a significant lower abundance of the genera Alloprevotella, Holdemanella, Erysipelotrichaceae_UCG-003, and Anaerobiospirillum and, conversely, a significant increase in the genera Escherichia-Shigella and Clostridium sensu stricto 1 in diseased dogs. At the phylum level, Bacteroidota was significantly reduced in diseased dogs (25% in controls vs. 19% in MCT dogs). In conclusion, sequencing analysis provided an overview of the bacterial profile and showed statistical differences in the microbial communities of dogs with MCT compared with healthy dogs, suggesting a link between the gut microbiota and MCT in this species.
Keywords: dog; dysbiosis; mast cell tumours; microbiota.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures




Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Study on the Correlation Between Aggressive Behavior and Gut Microbiota and Serum Serotonin (5-HT) in Working Dogs.Vet Sci. 2025 May 28;12(6):526. doi: 10.3390/vetsci12060526. Vet Sci. 2025. PMID: 40559763 Free PMC article.
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
References
-
- Willmann M., Hadzijusufovic E., Hermine O., Dacasto M., Marconato L., Bauer K., Peter B., Gamperl S., Eisenwort G., Jensen-Jarolim E., et al. Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. Vet. Comp. Oncol. 2019;17:1–10. doi: 10.1111/vco.12440. - DOI - PMC - PubMed
Grants and funding
- POCI-01-0246-FEDER-181287/RESOLVE Health 2.0 Innovation Acceleration Pro-407 gram - "Microbiome in Agro-Food & Health Biotech Living Lab" - financed by FEDER Thematic 408 Operational Program Competitiveness and Internationalization
- 2021.08598.BD/Fundação para a Ciência e Tecnologia
- 2022.07006.CEECIND/Fundação para a Ciência e Tecnologia
- UIDB/04423/2020/CIIMAR Strategic Funding
- UIDP/04423/2020/CIIMAR Strategic Funding
LinkOut - more resources
Full Text Sources